

GOVERNMENT OF PAKISTAN
THE PATENT OFFICE
2nd Floor, Kandawala Building,
M.A. Jinnah Road,
Karachi

No.2/2/2003-F.Sec.

Dated: 09-01-2007

To,

The Manager,
Printing Corporation of Pakistan Press,
University Road,
Karachi

Subject: **WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE
WEEK-ENDING 16-9-2006 TO BE PUBLISHED ON 09-1-2007
IN THE GAZETTE OF PAKISTAN PART-V.**

A manuscript copy of the weekly notification regarding application filed application accepted and scaling fee due etc., is forwarded herewith to be published in the next issue of the Gazette of Pakistan Part-V without fail.

(Mrs. Yasmeen Abbasi)
Controller of Patents & Designs
Ph: 9215488

ENCL:

NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

1153/2006	<u>11-9-2006</u> Pepfarm R & D Limited., Hong Kong (Priority 13-7-01 USA) Divisional	“ Biologically active peptide”
1154/2006	Pepfarm R & D Limited., Hong Kong (Priority 13-7-01 USA) Divisional	“ Biologically active peptide”
1155/2006	Wyeth, USA (Priority 12-9-05 USA)	“ Salicylate and gentisate salts of a piperazine compound”
1156/2006	Wyeth, USA (Priority 12-9-05 USA)	“ Sustained-released formulation and uses thereof”
1157/2006	Wyeth, USA (Priority 12-9-05 USA)	“ Glucuronate salt of a piperazine compound”
1158/2006	<u>12-9-2006</u> Cracol Developments Ltd, Cyprus (Priority 17-9-05 GB)	“ A device”
1159/2006	AstraZeneca AB., Sweden (Priority 20-9-05 Europe)	“ Chemical Compounds”
1160/2006	Bristol-Myers Squibb Company, USA (Priority 12-9-05 USA)	“ Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors”
1161/2006	Bristol-Myers Squibb Company, USA (Priority 13-9-05 USA)	“ Indolobenzazepine HCV NS5B inhibitors”

1162/2006	Janssen Pharmaceutica N.V., Belgium (Priority 14-9-05 USA)	“ Novel lysine salts of 4-((phenoxyalkyl)thio)-phenoxyacetic acid derivatives”
1163/2006	Unilever Plc., England (Priority 23-9-05 Europe)	“ Tea process”
	<u>13-9-2006</u>	
1164/2006	Honda Motor Co. Ltd., Japan (Priority 31-10-05 Japan)	“ Headlight supporting structure”
1165/2006	Limited Company TM., Japan (Priority 19-10-05 Japan)	“ Electric power storage system using capactors and control method thereof”
1166/2006	Veritron Limited., United Kingdom (Priority 22-9-05 Japan)	“ Enhancer of cholinesterase activity”
1167/2006	Otsuka Pharmaceutical Co. Ltd., Japan (Priority 15-9-05 USA)	“ Combination drug”
1168/2006	Honda Motor Co. Ltd., Japan (Priority 30-11-05 Japan)	“ Internal combustion engine”
1169/2006	IWICS Inc., USA (Priority 13-9-05 USA)	“ Position determination of mobile stations in a wireless network”
1170/2006	Wyeth Holding Corporation. USA (Priority 14-4-03 USA) Divisional	“ Compositions containing piperacillin and tazobactam useful for intravenous administration as antibiotics”
1171/2006	AstraZeneca AB., Japan (Priority 16-9-05 SE)	“ Novel Compounds”
1172/2006	AstraZeneca AB., Japan (Priority 22-9-05 SE)	“ Novel Compounds”
1173/2006	Bayer CropScience GmbH., Germany (Priority 16-9-05 Europe)	“ Solid formulation”

1174/2006	Bayer CropScience AG., Germany (Priority 16-9-05 Japan)	“ A use of sulfonanilides as herbicides”
1175/2006	Merck Patent GmbH., Germany (Priority 22-7-99 Germany) Divisional	“ Salt of N-(indolecarbonyl)piperazine derivative”
1176/2006	Merck Patent GmbH., Germany (Priority 22-7-99 Germany) Divisional	“ Solvate of N-(indolecarbonyl) piperazine derivative”
1177/2006	AstraZeneca UK Limited., United Kingdom (Priority 16-12-02 UK) Divisional	“ Process for the preparation of pyrimidine compound”
1178/2006	AstraZeneca UK Limited., United Kingdom (Priority 16-12-02 UK) Divisional	“ Process for the preparation of pyrimidine compound”
1179/2006	Janssen Pharmaceutica N.V., Belgium (Priority 27-3-98 USA) Divisional	“ Salt of Hiv-inhibiting pyrimidine derivative”
	<u>14-9-2006</u>	
1180/2006	Sumitomo Chemical Company, Limited., Japan (Priority 15-10-03 Japan) Divisional	“ A 1,2,4-thiadiazole compound and pest controlling composition containing the same”
1181/2006	AstraZeneca AB, Sweden (Priority 5-11-99 Europe) Divisional	“ A salt of quinazoline compound”
1182/2006	Altana Pharma AG., Germany (Priority 21-9-05 Europe)	“ Novel sulphonylpyrroles”
	<u>15-9-2006</u>	
1183/2006	Neuralab Limited., USA	“ A humanized immunoglobulin, or antigen-binding fragment thereof”

	(Priority 06-12-2000 USA) Divisional	
1184/2006	Neuralab Limited., USA (Priority 06-12-2000 USA) Divisional	“ A humanized immunoglobulin, or antigen-binding fragment thereof”
	<u>16-9-2006</u>	
1185/2006	Janssen Pharmaceutica N.V., Belgium (Priority 16-9-05 USA)	“ Cyclopropyl amines as modulators of the histamine H3 receptor”
1186/2006	Honeywell International, Inc., USA (Priority 16-9-05 USA)	“ Reinforced plastic pipe”
1187/2006	Altana Pharma AG., Germany (Priority 21-9-05 Europe)	“ Novel sulphonylpyrroles”
1188/2006	1.Cytokinetics, Inc., 2. SmithKline beecham Corporation, USA (Priority 11-10-02 USA) Divisional	“ A pharmaceutically acceptable salt of a 1,2,4-triazole-5-one compound for treating cellular proliferative diseases and disorders”
1189/2006	Monsanto Technology LLC, USA (Priority 16-9-05 USA)	“Methods for genetic control of insect infestations in plants and compositions thereof”

SEALING FEES DUE

Notice is hereby given that the Patent may now be sealed on the application referred to below if it is desired that Patent should be sealed a request on the prescribed Form-10 accompanied by the fee of Rs.2250/- should be sent to the Controller of Patents and Designs, The Patent Office, Karachi.

139059

Unilever Plc.,

631/2004

United Kingdom

139060	Clipsal Australia Pty Ltd. Australia	632/2004
139061	H. Lundbeck A/S Denmark	636/2004
139062	22 nd Century Limited LLC., USA	639/2004
139063	SmithKline Beecham (Cork) Ltd Eire	640/2004
139064	Vital Earth Technologies Pty. Ltd Australia	641/2004
139065	Nokia Corporation. Finland	649/2004
139066	Novartis AG., Switzerland	661/2004
139067	H. Lundbeck A/S Denmark	415/2006

(Mrs. Yasmeen Abbasi)
Controller of Patents & Designs

Tel: 9215488